FDA Seeks To Include Those Most Affected By Alzheimer’s Disease In The Drug Review Process
Nov 18th 2007Drug InformationAlzheimer's / Dementia News XML/RSS Feed
The U.S. Food and Drug Administration (FDA) has expanded its Patient Consultant and Patient Representative programs to include individuals in the early stages of Alzheimer’s disease and their caregivers. The FDA made the change in response to a request by the Alzheimer’s Association encouraging the agency to give people directly affected by Alzheimer’s a more active role in the review and approval of new Alzheimer drugs. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
